We have located links that may give you full text access.
Prevention of Portal-Tract Fibrosis in Zfyve19 -/- Mouse Model with Adeno-Associated Virus Vector Delivering ZFYVE19 .
Human Gene Therapy 2023 September 7
Zinc finger FYVE-type containing 19 (ZFYVE19) deficiency, caused by biallelic ZFYVE19 complete loss-of-function variants, is a recently identified chronic hepatobiliary disorder characterized by obvious portal-tract fibrosis, increased numbers of bile ducts with malformations, and abnormal levels of serum markers of hepatobiliary injury. As liver-targeted adeno-associated virus (AAV) gene therapy has been used successfully in hepatobiliary diseases, liver-targeted gene therapy has been explored in a mouse model of this disorder. Three ZFYVE19 AAV vectors (AAV- hZFYVE19 , AAV- hZFYVE19-m , and AAV- hZFYVE19-co ) were constructed and injected into Zfyve19-/- mice, which were treated with alpha-naphthyl isothiocyanate (ANIT), a hepatobiliary toxin. Hematoxylin/eosin (H&E), immunohistochemical (IHC) staining, immunofluorescence (IF) staining, Sirius red staining, RT-qPCR, and western blotting (WB) of liver tissue, along with serum hepatobiliary injury markers analyses, were performed to evaluate the effects of gene therapy. AAV- hZFYVE19 decreased serum hepatobiliary injury markers, portal-tract inflammation, ductal hyperplasia, and portal-tract fibrosis in Zfyve19-/- model mice most substantially at a relatively low dose (1 × 1011 vg/kg), whereas AAV- hZFYVE19 at a higher dose gradually lost the above-mentioned benefits and even caused deterioration at the highest dose of 5 × 1012 vg/kg. These observations verified the pathogenicity of ZFYVE19 deficiency and suggested that the ZFYVE19 gene needs to function well at an optimal level of expression; both too low or too high ZFYVE19 expression may be harmful.
Full text links
Related Resources
Trending Papers
Haemodynamic monitoring during noncardiac surgery: past, present, and future.Journal of Clinical Monitoring and Computing 2024 April 31
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.Circulation 2024 May 9
Obesity pharmacotherapy in older adults: a narrative review of evidence.International Journal of Obesity 2024 May 7
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app